METHODS
In this study, 44 US hospitals collected non-duplicate, non-urine Escherichia coli CLSI states that the initial MIC-based ESBL screening for E. coli and K. pneumoniae should be performed by evaluating the MIC profile of one of the following drugs: cefpodoxime 4 lg/mL, CAZ 1 lg/mL, ATM 1 lg/mL, or cefotaxime 1 lg/mL. It is noted that the use of more than one of these agents will improve detection of ESBLs. We defined a positive ESBL screen as having an MIC of C1 lg/mL to 2 of the following: ATM, CRO, or CAZ. Subsequent CLSI defined, phenotypic, ESBL confirmation studies were undertaken using CAZ and cefotaxime with and without clavulanate [8] .
Probable carbapenemase-producing organisms were excluded based on ETP (C1 lg/mL) or MEM (C2 lg/mL) susceptibility profiles. While molecular-based confirmation of these enzymes would have been definitive, methodologies readily available to the clinical microbiology laboratory were utilized. Percent susceptibility (%S) was based on CLSI breakpoints [3] . Recently, C/T has been approved in the US and susceptibility interpretative criteria have now been provided by the FDA of B2 lg/mL for the Enterobacteriaceae [7] .
This surveillance program was reviewed by the institutional review board (IRB) at the coordinating center, Hartford Hospital. Since all samples were collected as part of routine 
